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States?––Response to Grandjour
Afschin Gandjour raises an interesting point that we
did not explore in our paper [1]: the discrepancy
between the higher return on investment (ROI) we
calculated for innovations for coronary heart disease
following acute myocardial infarction, type 2 diabetes,
and stroke relative to the overall ROI to Medicare for
these same diseases. In his attempt to account for this
inconsistency in our ﬁndings, he notes (correctly) that
the cost-effectiveness analyses (CEAs) of speciﬁc treat-
ments do not incorporate the costs of overuse, rather
they consider only appropriate care. Furthermore, he
suggests that substantial treatment overuse of medical
care in the United States may be the main reason for its
relatively lower ROI. This could be, but we do not
think there is sufﬁcient evidence to draw such an infer-
ence for the following reasons.
First, the technologies we chose to review for ROI
were selected as being the major innovations over the
past 20 or so years and for which CEAs had been
published. So each technology was a special, high
proﬁle case in contrast to all of medical care for the
diseases in question. We had no expectation that indi-
vidually or collectively they would be indicative of
overall medical care. Second, the ROIs for the tech-
nologies were not focused on the Medicare population
of more than 65 years old. Third, whereas overuse of
medical care in the elderly population undoubtedly
occurs, so does underuse, including incomplete pre-
scribing and poor adherence to medications.
Thus, we would suggest that Dr Gandjour’s com-
ments are speculative at this point.––Bryan R. Luce,
PhD, MBA, United BioSource Corporation, Bethesda,
MD, USA.
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